Mydecine's lead drug candidate, MYCO-001 will be used in a major, new smoking cessation clinical study by Johns Hopkins.
Mydecine's lead drug candidate, MYCO-001 will be used in a major, new smoking cessation clinical study by Johns Hopkins.
Mydecine spins out the company's cannabis assets into a private subsidiary, to comply with with the regulatory requirements of both the NASDAQ and London Stock Exchange.
MINDCURE announces its addition to the OTCQX Best Markets tier.
Novamind opens the 6th mental health clinic in its Cedar Psychiatry network, located in Murray, Utah. Novamind is now projecting a total of 65,000 clinic visits this year.
Private company Delix Therapeutics raises $70 million, focusing on non-hallucinatory candidates to treat brain disorders.
MINDCURE launches "Desire Project", taking a psychotherapy approach to female hypocactive sexual disorder.
MindMed provides updates on two of its research initiatives, in partnership with the Liechti Lab (Switzerland).
Levitee Labs announces that its shares are now eligible for clearing through the DTC.
Novamind announces that its shares are now eligible for electronic clearing through the DTC.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now